These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18222602)

  • 21. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of immunotherapy on bladder cancer].
    Watanabe K; Suzuki T; Takahashi N; Kawaguchi T; Kudo T; Kogawa T; Funyu T
    Nihon Hinyokika Gakkai Zasshi; 1987 Jun; 78(6):1092-102. PubMed ID: 3682501
    [No Abstract]   [Full Text] [Related]  

  • 24. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
    Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
    J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Editorial comment on: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.
    Soloway MS
    Eur Urol; 2008 Aug; 54(2):313-4. PubMed ID: 18468783
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH).
    Lamm DL; DeHaven JI; Riggs DR; Ebert RF
    J Urol; 1993 Mar; 149(3):648-52. PubMed ID: 8437283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic anti-hyperalgesia of electroacupuncture and low dose of celecoxib in monoarthritic rats: involvement of the cyclooxygenase activity in the spinal cord.
    Mi WL; Mao-Ying QL; Liu Q; Wang XW; Wang YQ; Wu GC
    Brain Res Bull; 2008 Sep; 77(2-3):98-104. PubMed ID: 18721668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Gúerin immunotherapy.
    Gofrit ON; Pode D; Pizov G; Zorn KC; Katz R; Duvdevani M; Shapiro A
    Urol Oncol; 2009; 27(3):258-62. PubMed ID: 18440839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy?
    Gofrit ON; Pode D; Pizov G; Zorn KC; Katz R; Shapiro A
    BJU Int; 2009 Apr; 103(7):905-8. PubMed ID: 19021623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mild renal insufficiency in a 70-year-old male with bladder carcinoma].
    Vallés M; Modesto A; de Marion C
    Med Clin (Barc); 1993 Mar; 100(12):469-74. PubMed ID: 8479221
    [No Abstract]   [Full Text] [Related]  

  • 31. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
    Chen F; Zhang G; Cao Y; Hessner MJ; See WA
    J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.
    Sooriakumaran P; Coley HM; Fox SB; Macanas-Pirard P; Lovell DP; Henderson A; Eden CG; Miller PD; Langley SE; Laing RW
    Anticancer Res; 2009 May; 29(5):1483-8. PubMed ID: 19443354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of BCG immunotherapy on cell-mediated cytotoxicity in bladder cancer patients following surgical treatment.
    Antonaci S; Piccinno A; Lucivero G; Miglietta A; Piccininno A; Bonomo L
    Tumori; 1981; 67(3):177-82. PubMed ID: 6974423
    [No Abstract]   [Full Text] [Related]  

  • 34. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.
    Hawk E; Viner JL
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):185-7. PubMed ID: 17301246
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunotherapy: The development of immunotherapy in urothelial bladder cancer.
    Powles T
    Nat Rev Clin Oncol; 2015 Apr; 12(4):193-4. PubMed ID: 25781573
    [No Abstract]   [Full Text] [Related]  

  • 36. Bladder cancer.
    Droller MJ
    J Urol; 1994 Nov; 152(5 Pt 1):1434. PubMed ID: 7933177
    [No Abstract]   [Full Text] [Related]  

  • 37. [BCG infection of the glans penis after intravesical BCG therapy].
    Michelet N; Spenatto N; Viraben R; Cuny JF; Mazet J; Trechot P; Barbaud A; Schmutz JL
    Ann Dermatol Venereol; 2008; 135(6-7):479-83. PubMed ID: 18598797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impressive regression of visceral and cerebral melanoma metastases under combination treatment including dacarbacine, radiotherapy and celecoxib.
    Becker MR; Gaiser T
    Int J Dermatol; 2009 Feb; 48(2):207-9. PubMed ID: 19200209
    [No Abstract]   [Full Text] [Related]  

  • 39. [Immunotherapy of bladder carcinoma].
    Damianov Kh; Koleva P; Patrashkov T
    Khirurgiia (Sofiia); 1987; 40(6):35-41. PubMed ID: 3325689
    [No Abstract]   [Full Text] [Related]  

  • 40. Bladder cancer: clinical practice.
    Rabinowits G; Laber DA
    J Ky Med Assoc; 2009 Apr; 107(4):129-33. PubMed ID: 19419018
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.